Sec Form 4 Filing - ABG WTT-MedAvail Ltd @ MedAvail Holdings, Inc. - 2020-12-18

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
ABG WTT-MedAvail Ltd
2. Issuer Name and Ticker or Trading Symbol
MedAvail Holdings, Inc. [ MDVL]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director X __ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TOWER, THE LANDMARK
3. Date of Earliest Transaction (MM/DD/YY)
12/18/2020
(Street)
HONG KONG, K3
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_____ Form filed by One Reporting Person
__ X __ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/18/2020 P 10,192 A $ 13.5946 ( 1 ) 3,840,092 I See Footnote ( 2 )
Common Stock 12/18/2020 P 8,408 A $ 13.5946 ( 1 ) 2,882,947 I See Footnote ( 3 )
Common Stock 12/21/2020 P 8,919 A $ 13.3147 ( 4 ) 3,849,011 I See Footnote ( 2 )
Common Stock 12/21/2020 P 7,358 A $ 13.3147 ( 4 ) 2,890,305 I See Footnote ( 3 )
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ABG WTT-MedAvail Ltd
UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK
HONG KONG, K3
X
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK, CENTRAL
HONG KONG, K3
X
ABG-WTT Global Life Science Capital Partners GP, L.P.
UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK, CENTRAL
HONG KONG, K3
X
ABG-WTT Global Life Science Capital Partners GP Ltd
UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK, CENTRAL
HONG KONG, K3
X
ABG Management Ltd.
UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK, CENTRAL
HONG KONG, K3
X
Yu Fan
UNIT 3002-3004, 30TH FLOOR
GLOUCESTER TOWER, THE LANDMARK, CENTRAL
HONG KONG, K3
X
Ally Bridge MedAlpha Master Fund L.P.
430 PARK AVENUE, 12TH FLOOR,
NEW YORK, NY10022
X
Ally Bridge MedAlpha Management L.P.
430 PARK AVENUE, 12TH FLOOR,
NEW YORK, NY10022
X
Ally Bridge MedAlpha Management GP, LLC
430 PARK AVENUE, 12TH FLOOR,
NEW YORK, NY10022
X
Ally Bridge Group (NY) LLC
430 PARK AVENUE, 12TH FLOOR,
NEW YORK, NY10022
X
Signatures
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P., By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner, By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu, Director 12/22/2020
Signature of Reporting Person Date
ABG-WTT Global Life Science Capital Partners GP, L.P., By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu, Director 12/22/2020
Signature of Reporting Person Date
ABG-WTT Global Life Science Capital Partners GP Limited, By: /s/ Fan Yu, Director 12/22/2020
Signature of Reporting Person Date
Ally Bridge MedAlpha Master Fund L.P., By: Ally Bridge MedAlpha General Partner L.P., its general partner, By: Ally Bridge MedAlpha GP, LLC, its general partner, By: /s/ Fan Yu, Manager 12/22/2020
Signature of Reporting Person Date
Ally Bridge MedAlpha Management L.P., By: Ally Bridge MedAlpha Management GP, LLC, its general partner, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director 12/22/2020
Signature of Reporting Person Date
Ally Bridge MedAlpha Management GP, LLC, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director 12/22/2020
Signature of Reporting Person Date
Ally Bridge Group (NY) LLC, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director 12/22/2020
Signature of Reporting Person Date
ABG Management Ltd., By: /s/ Fan Yu, Director 12/22/2020
Signature of Reporting Person Date
ABG WTT-MedAvail Limited, By: /s/ Charles Chon, Director 12/22/2020
Signature of Reporting Person Date
/s/ Fan Yu 12/22/2020
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.38 to $13.84. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
( 2 )These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
( 3 )These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.
( 4 )The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.